<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019032</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064038</org_study_id>
    <secondary_id>NCI-95-C-0054K</secondary_id>
    <nct_id>NCT00019032</nct_id>
    <nct_alias>NCT00001425</nct_alias>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the toxicity of murine monoclonal antibody Mik-beta-1 (MOAB Mik-beta-1) in&#xD;
           patients with T-cell large granular lymphocytic leukemia associated with&#xD;
           granulocytopenia, anemia, or thrombocytopenia.&#xD;
&#xD;
        -  Determine the clinical response in patients treated with this drug.&#xD;
&#xD;
        -  Assess the effect of this drug on the number of circulating CD3+, CD8+ expressing&#xD;
           granular lymphocytes and the number of polymorphonuclear leukocytes, red blood cells,&#xD;
           and platelets in this patient population.&#xD;
&#xD;
        -  Monitor patients for the time course of decline in circulating infused MOAB Mik-beta-1&#xD;
           and for the production of human antibodies to IV infused murine MOAB Mik-beta-1.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive monoclonal antibody Mik-beta-1 (MOAB Mik-beta-1) IV over 2 hours on days 1,&#xD;
      4, 7, and 10. Patients achieving a complete response (CR) or partial response (PR) may&#xD;
      receive 1 additional course beginning no sooner than 4 weeks after completion of the first&#xD;
      course, in the absence of antibodies to MOAB Mik-beta-1. Treatment continues in the absence&#xD;
      of disease progression, unacceptable toxicity, or severe allergic reaction.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MOAB Mik-beta-1 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 6-10 days and at 4-6 weeks after therapy. Patients with a PR or CR&#xD;
      may be followed every 6 months for 2 years or until relapse. All patients are followed for&#xD;
      survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody Mik-beta-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed T-cell large granular lymphocytic (T-LGL) leukemia associated&#xD;
             with clinically significant hematocytopenia demonstrated by one of the following&#xD;
             values while off growth factor support:&#xD;
&#xD;
               -  Absolute neutrophil count less than 1,000/mm^3&#xD;
&#xD;
               -  Hemoglobin less than 8 g/dL&#xD;
&#xD;
               -  Platelet count less than 50,000/mm^3&#xD;
&#xD;
          -  Clinically evaluable disease with peripheral blood T-LGL leukemia cells expressing the&#xD;
             CD3+, CD8+ phenotype detectable by FACS&#xD;
&#xD;
          -  Monoclonal T-cell population in peripheral blood (circulating mononuclear cells)&#xD;
             demonstrated by TCR beta or gamma chain gene rearrangement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No active major bleeding episode within the past 4 weeks&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Direct bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent serious active infection&#xD;
&#xD;
          -  Patients with fever without apparent site of infection may begin study while on&#xD;
             antibiotics as long as the following are true:&#xD;
&#xD;
               -  No pathogenic organism in culture&#xD;
&#xD;
               -  Afebrile (maximum temperature less than 38Â°C) for at least 5 days&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other primary cancer other than basal cell skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior interferon&#xD;
&#xD;
          -  Concurrent filgrastim (G-CSF), sargramostim (GM-CSF), interleukin-11, or similar&#xD;
             sustained-release/long-acting product (e.g., pegylated G-CSF) allowed if dose&#xD;
             established at least 4 weeks prior to study participation&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed if dose established at least 3 weeks prior to study&#xD;
             participation&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 week since completion of prior antibiotic regimen for serious infectious&#xD;
             episode&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A. Waldmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Metabolism Branch;MET</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

